Introduction. Both dyslipidemia and osteoporosis are chronic medical problems, and the relationship between these two pathologies is based on common risk factors and pathogenic mechanisms which favour the development of both diseases. Dyslipidemia can be a risk factor for osteoporosis, therefore it is important to understand the mechanisms underlying the relation between these two pathologies. The link between dyslipidemia and osteoporosis. Lipoprotein oxidation products suppress the differentiation of osteoblasts while stimulating the differentiation of adipocytes and their proliferation, a mechanisms that can contribute to the reduction of bone mineralization and the occurrence of inflammatory events. A number of clinical and experimental studies have been performed, these studies suggesting an inverse correlation between the adipose content of the bone marrow and the density of the bone tissue, in other words, in parallel with the osteoporotic bone loss there is an increase of the adipocyte content in the bone marrow. The role of plasma lipids on bone metabolism. Because in clinic patients with dyslipidemia are often diagnosed with osteoporosis, we can say that serum levels of plasma lipids influence both osteoblastic and osteoclastic activity. Cholesterol correlates with low bone mineral density, while triglycerides are associated with a low incidence of vertebral fractures in osteoporotic women. Effects of lipid-lowering medication on bone tissue. Statins, first introduced to treat patients with hyperlipidemia and hypercholesterolemia, have also been shown to be beneficial for osteoporotic patients and have recently been introduced to prevent fractures and treat osteoporosis through their ability to enhance osteogenesis and inhibit osteoclastogenesis. Conclusions.There is a wide range of studies that have shown that statins, widely used as lipid-lowering agents, could also be utilized in the treatment of osteoporosis, through the beneficial effects they have on bone metabolism, effects with a positive impact on bone mineral density.
To Assess The Ability of CBCT in Evaluating Osteoporotic Bone Changes in Type 2 Diabetes Mellitus Patients in Comparison to Bone Mineral Density using DEXA
